NCT00126438View on ClinicalTrials.gov

Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

515

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

July 31, 2008

Study Completion Date

September 30, 2008

Conditions
Heart Failure, Congestive
Interventions
DRUG

123I-mIBG (meta-iodobenzylguanidine)

Single Dose

Trial Locations (1)

08540

GE Healthcare, Princeton

Sponsors

Lead Sponsor

GE Healthcare
All Listed Sponsors
lead

GE Healthcare

INDUSTRY

NCT00126438 - Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease | Biotech Hunter | Biotech Hunter